НЕРЕШЕННЫЕ ВОПРОСЫ В СОВРЕМЕННОЙ ТАКТИКЕ ВЕДЕНИЯ ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ

В данной статье рассмотрены основные дискуссионные и нерешенные разделы в лечении пациентов с фибрилляцией предсердий, а именно открытые вопросы антикоагулянтной, антиаритмической, интервенционной и хирургической тактик ведения пациентов с данной аритмией. Обсуждаются недостатки и “слабые места” современных терапевтических и хирургический стратегий, а также классификации фибрилляции предсердий, вопросы оптимальной тактики контроля ритма больных с ФП и раннего выявления данного нарушения ритма сердца. Каждая из этих проблем связана с рядом возможностей для лучшего понимания развития этой аритмии и ведения таких пациентов.

1. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J (2016) 37 (38): 2893-962; doi: 10.1093/eurheartj/ehw210.

2. Fabritz L, Guasch E, Antoniades C, et al. Expert consensus document: defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. Nature Reviews Cardiology (2016). 13: 230-7; doi: 10.1038/nrcardio.2015.194.

3. Van Wagoner DR, Piccini JP, Albert CM, et al. Progress toward the prevention and treatment of atrial fibrillation: a summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. Heart rhythm: the official journal of the Heart Rhythm Society 12.1 (2015): e5-e29; doi: 10.1016/j.hrthm.2014.11.011.

4. Svennberg E, Engdahl J, Al-Khalili F, et al. Mass screening for untreated atrial fibrillation: the STROKESTOP study. Circulation (2015): 131: 2176-84; doi: 10.1161/CIRCULATIONAHA.114.014343.

5. Reiffel JA, et al. REVEAL-AF: Silent AF common in high-risk patients. C-LBCT02-05. Presented at: Heart Rhythm Society Annual Scientific Sessions; May 10-13, 2017; Chicago.

6. Ko D, Rahman F, Schnable RB, et al. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nature Reviews Cardiology 13.6 (2016): 321-32; doi: 10.1038/nrcardio.2016.45.

7. Shanmugam N, Boerdlein A, Proff J, et al. Detection of atrial high-rate events by continuous Home Monitoring: clinical significance in the heart failure–cardiac resynchronization therapy population. Europace 14.2 (2012): 230-7; doi: 10.1093/europace/eur293.

8. Ricci RP, Morichelli L, D’Onofrio A, et al. Effectiveness of remote monitoring of CIEDs in detection and treatment of clinical and device-related cardiovascular events in daily practice: the HomeGuide Registry. Europace (2013): 15 (7): 970-7; doi: 10.1093/europace/eus440.

9. Santini L, Santini M. The role of implantable devices to treat atrial fibrillation. Future cardiology 11.6 (2015): 689-95; doi:10.2217/fca.15.61.

10. Botto GL, Padeletti L, Santini M, et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. Journal of cardiovascular electrophysiology 20.3 (2009): 241-248; doi: 10.1111/j.15408167.2008.01320.x

11. Glotzer TV, Hellkamp AS, Zimmerman J, et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke. Circulation 107.12 (2003): 1614-9; doi: 10.1161/01.CIR.0000057981.70380.45

12. Main ML, Fan D, Reddy VY, et al. Assessment of device-related thrombus and associated clinical outcomes with the WATCHMAN left atrial appendage closure device for embolic protection in patients with atrial fibrillation (from the PROTECT-AF trial). The American journal of cardiology 117.7 (2016): 1127-34; doi:10.1016/j.amjcard.2016.01.039.

13. Boersma LV, Schmidt B, Betts TR. et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. European heart journal (2016): 37 (31): 2465-74; doi:10.1093/eurheartj/ehv730.

14. Boersma LV, Schmidt B, Betts TR, et al. EWOLUTION investigators. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J 2016; 37: 2465-74; doi: 10.1093/eurheartj/ehv730.

15. Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. Jama 313.8 (2015): 824-36; doi: 10.1001/jama.2015.0846.

16. Nielsen PB, Larsen TB, Skjøth F, et al. Restarting anticoagulant treatment after intracranial haemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality and bleeding: a Nationwide Cohort Study. Circulation (2015): 132: 517-25; doi:10.1161/CIRCULATIONAHA.115.015735.

17. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. New England Journal of Medicine 364.9 (2011): 806-17; doi: 0.1056/NEJMoa1007432.

18. Airaksinen KE, Grönberg T, Nuotio I, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation. Journal of the American College of Cardiology 62.13 (2013): 1187-92; doi:10.1016/j.jacc.2013.04.089.

19. Nuotio I, Hartikainen JE, Grönberg T, et al. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. Jama 312.6 (2014): 647-9; doi: 10.1001/jama.2014.3824.

20. Grönberg T, Nuotio I, Nikkinen M, et al. Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: the FinCV study. Europace 15.10 (2013): 1432-5; doi: 10.1093/europace/eut106.

21. Tse HF, Lau CP. Does sinus rhythm beget sinus rhythm? Effects of prompt cardioversion on the frequency and persistence of recurrent atrial fibrillation. Cardiac electrophysiology review 7.4 (2003): 359-65; doi: 10.1023/B:CEPR.0000023139.45437.93.

22. Van Gelder IC, Hemels ME. The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm. Europace 8.11 (2006): 943-9; doi:/10.1093/europace/eul107.

23. Liu ZJ, Fu WG, Guo ZY, et al. Updated systematic review and meta-analysis of randomized clinical trials comparing carotid artery stenting and carotid endarterectomy in the treatment of carotid stenosis. Annals of vascular surgery 26.4 (2012): 576-90; doi: 10.1016/j.avsg.2011.09.009.

24. Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. The Lancet 353.9171 (1999): 2179-84; doi: 10.7326/ACPJC-2000-132-1-010.

25. Watanabe M, Chaudhry SA, Adil MM, et al. The effect of atrial fibrillation on outcomes in patients undergoing carotid endarterectomy or stent placement in general practice. Journal of vascular surgery 61.4 (2015): 927-32; doi: 10.1016/j.jvs.2014.11.001.

26. Breithardt G, Baumgartner H, Berkowitz SD, et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. European heart journal 35.47 (2014): 3377-85; doi:10.1093/eurheartj/ehu305.

27. Philippart R, Brunet-Bernard A, Clementy N, et al. Prognostic value of CHA2 DS2 -VASc score in patients with ‘non-valvular atrial fibrillation’and valvular heart disease: the Loire Valley Atrial Fibrillation Project. European heart journal 36.28 (2015): 1822-30; doi: 10.1093/eurheartj/ehv163.

28. Breithardt G, Baumgartner H. Valvular heart disease among non-valvular atrial fibrillation: a misnomer, in search of a new term. (2015): 1794-7; doi:10.1093/eurheartj/ehv193.

29. ClinicalTrials.gov. Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATEAF). https://clinicaltrials.gov/ct2/show/NCT02391337.

30. Duytschaever M, et al. Pulmonary vein isolation with versus without continued antiarrhythmic drug treatment in subjects with recurrent atrial fibrillation: results from the powder af multicentre randomised trial. LBCT02-04. Presented at: Heart Rhythm Society Annual Scientific Sessions; May 10-3, 2017; Chicago.

31. Kirchhof P, Calkins H. Catheter ablation in patients with persistent atrial fibrillation. European heart journal (2017): 38 (1): 20-6; doi: 10.1093/eurheartj/ehw260.

32. Verma A, Jiang CY, Betts TR, et al. Approaches to catheter ablation for persistent atrial fibrillation. New England Journal of Medicine 372.19 (2015): 1812-22; doi: 10.1056/ NEJMoa1408288.

33. Wolf RK, Schneeberger EW, Osterday R, et al. Video-assisted bilateral pulmonary vein isolation and left atrial appendage exclusion for atrial fibrillation. The Journal of Thoracic and Cardiovascular Surgery 130.3 (2005): 797-802; doi:10.1016/j.jtcvs.2005.03.041.

34. Yilmaz A, Van Putte BP, Van Boven WJ. Completely thoracoscopic bilateral pulmonary vein isolation and left atrial appendage exclusion for atrial fibrillation. The Journal of thoracic and cardiovascular surgery 136.2 (2008): 521-2; doi:10.1016/j.jtcvs.2008.01.035. 3

35. Weimar T, Vosseler M, Czesla M, et al. Approaching a paradigm shift: endoscopic ablation of lone atrial fibrillation on the beating heart. The Annals of Thoracic Surgery 94.6 (2012): 1886-92; doi:10.1016/j.athoracsur.2012.07.035.

36. Whitlock R, Healey J, Vincent J, et al. Rationale and design of the left atrial appendage occlusion study (LAAOS) III. Annals of cardiothoracic surgery 3.1 (2014): 45-54; doi:10.3978/j.issn.2225-319X.2013.12.06.

37. Salzberg SP, Plass A, Emmert MY, et al. Left atrial appendage clip occlusion: early clinical Results. The Journal of Thoracic and Cardiovascular Surgery 139.5 (2010): 1269-74; doi:10.1016/j.jtcvs.2009.06.033.

38. Papworth Hospital NHS Foundation Trust. A randomised controlled trial to investigate the clinical and cost effectiveness of adding an ablation device-based maze procedure as a routine adjunct to elective cardiac surgery for patients with pre-existing atrial fibrillation. http://www.isrctn.com/ISRCTN82731440.